| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2428582 | Comparative Immunology, Microbiology and Infectious Diseases | 2010 | 8 Pages |
Abstract
The aim of this study was to evaluate, in terms of dog macrophage killing ability in vitro, a vaccine based on Leishmania infantum promastigote soluble antigen (LSA) formulated with three different adjuvants (BCG, AdjuPrime™, MPL/TDM/CWS).A significant increase of the macrophage killing ability was observed in dogs vaccinated with LSA + MPL/TDM/CWS after 1 month from vaccination. A similar increase of macrophage parasitocidal ability was present only after 5 months in dogs vaccinated with LSA + BCG or LSA + AdjuPrime™. In all dogs the augmented killing percentage was still present after 12 months from vaccination. Therefore, in particular LSA + MPL/TDM/CWS vaccine seems promising for further studies in dogs.
Related Topics
Life Sciences
Agricultural and Biological Sciences
Animal Science and Zoology
Authors
T. Trotta, A. Fasanella, D. Scaltrito, L. Gradoni, V. Mitolo, O. Brandonisio, A. Acquafredda, M.A. Panaro,